We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$29.5B
$105M 1.02%
979,104
+114,332
+13% +$11M
CNC icon
27
Centene
CNC
$32.8B
$101M 0.99%
1,386,297
+95,700
+7% +$6.56M
HALO icon
28
Halozyme
HALO
$9.2B
$101M 0.99%
2,224,466
-787,500
-26% -$34.9M
BSX icon
29
Boston Scientific
BSX
$65.7B
$99.5M 0.97%
2,326,787
– –
TNDM icon
30
Tandem Diabetes Care
TNDM
$1.21B
$99.4M 0.97%
1,020,368
+493,234
+94% +$44M
SWAV
31
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$98.1M 0.96%
516,915
+32,351
+7% +$5.29M
BMY icon
32
Bristol-Myers Squibb
BMY
$124B
$97.8M 0.95%
1,463,432
-621,720
-30% -$40.5M
JAZZ icon
33
Jazz Pharmaceuticals
JAZZ
$15.4B
$96.8M 0.94%
544,750
-5,900
-1% -$1.02M
RLAY icon
34
Relay Therapeutics
RLAY
$4.24B
$96.6M 0.94%
2,640,962
+709,618
+37% +$23.4M
ALGN icon
35
Align Technology
ALGN
$12.6B
$95.8M 0.94%
156,770
+12,810
+9% +$7.58M
ESPR
36
DELISTED
Esperion Therapeutics
ESPR
$95.6M 0.93%
4,519,164
+530,000
+13% +$12.8M
ACCD
37
DELISTED
Accolade Inc
ACCD
$93.7M 0.91%
1,724,699
+163,578
+10% +$7.95M
EW icon
38
Edwards Lifesciences
EW
$49.3B
$92.2M 0.9%
890,256
– –
SYK icon
39
Stryker
SYK
$123B
$89.5M 0.87%
344,514
– –
INSM icon
40
Insmed
INSM
$23.5B
$88.8M 0.87%
3,120,901
+643,735
+26% +$19.1M
PODD icon
41
Insulet
PODD
$11.6B
$88.4M 0.86%
322,119
-112,069
-26% -$30.5M
BEAM icon
42
Beam Therapeutics
BEAM
$2.75B
$78.9M 0.77%
612,821
+46,000
+8% +$3.67M
EVH icon
43
Evolent Health
EVH
$650M
$76.8M 0.75%
3,638,411
+109,864
+3% +$2.2M
HRC
44
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$76.5M 0.75%
673,878
+13,250
+2% +$1.48M
MTEM
45
DELISTED
Molecular Templates, Inc.
MTEM
$75.3M 0.74%
641,908
+98,701
+18% +$12.9M
IDXX icon
46
Idexx Laboratories
IDXX
$44.8B
$74.6M 0.73%
118,120
+26,871
+29% +$14.8M
BAX icon
47
Baxter International
BAX
$11.5B
$72.5M 0.71%
900,623
+426,000
+90% +$35.7M
INSP icon
48
Inspire Medical Systems
INSP
$1.5B
$72.1M 0.7%
373,226
+53,038
+17% +$10.5M
NKTR icon
49
Nektar Therapeutics
NKTR
$2.22B
$70.4M 0.69%
273,427
+9,787
+4% +$2.71M
EPIX
50
DELISTED
ESSA Pharma
EPIX
$70.3M 0.69%
2,459,814
+634,000
+35% +$18.4M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.